- Home
- AKBA vs TELO Comparison
AKBA vs TELO Comparison
Compare AKBA & TELO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- TELO
- Stock Information
- Founded
- AKBA 2007
- TELO 2021
- Country
- AKBA United States
- TELO United States
- Employees
- AKBA N/A
- TELO N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- TELO
- Sector
- AKBA Health Care
- TELO
- Exchange
- AKBA Nasdaq
- TELO NYSE
- Market Cap
- AKBA 293.4M
- TELO 155.2M
- IPO Year
- AKBA 2014
- TELO 2024
- Fundamental
- Price
- AKBA $1.35
- TELO $5.15
- Analyst Decision
- AKBA Strong Buy
- TELO
- Analyst Count
- AKBA 2
- TELO 0
- Target Price
- AKBA $5.75
- TELO N/A
- AVG Volume (30 Days)
- AKBA 1.9M
- TELO 135.3K
- Earning Date
- AKBA 11-06-2024
- TELO 08-13-2024
- Dividend Yield
- AKBA N/A
- TELO N/A
- EPS Growth
- AKBA N/A
- TELO N/A
- EPS
- AKBA N/A
- TELO N/A
- Revenue
- AKBA $174,497,000.00
- TELO N/A
- Revenue This Year
- AKBA N/A
- TELO N/A
- Revenue Next Year
- AKBA $3.23
- TELO N/A
- P/E Ratio
- AKBA N/A
- TELO N/A
- Revenue Growth
- AKBA N/A
- TELO N/A
- 52 Week Low
- AKBA $0.78
- TELO $3.11
- 52 Week High
- AKBA $2.48
- TELO $20.72
- Technical
- Relative Strength Index (RSI)
- AKBA 45.89
- TELO N/A
- Support Level
- AKBA $1.27
- TELO N/A
- Resistance Level
- AKBA $1.58
- TELO N/A
- Average True Range (ATR)
- AKBA 0.09
- TELO 0.00
- MACD
- AKBA -0.02
- TELO 0.00
- Stochastic Oscillator
- AKBA 25.81
- TELO 0.00
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About TELO TELOMIR PHARMACEUTICALS INC
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.